nach oben

Journal of Neural Transmission

Erschienen in:

01.07.2014 | Psychiatry and Preclinical Psychiatric Studies - Original Article

An association between the reduced levels of SLC1A2 and GAD1 in the dorsolateral prefrontal cortex in major depressive disorder: possible involvement of an attenuated RAF/MEK/ERK signaling pathway

verfasst von: Dong Hoon Oh, Daeyoung Oh, Hyeon Son, Maree J. Webster, Cyndi S. Weickert, Seok Hyeon Kim

Erschienen in: Journal of Neural Transmission | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Previous human postmortem studies have shown that expression of glutamate transporters (SLC1A2 and SLC1A3) and gamma-aminobutyric acid-synthesizing enzyme [glutamic acid decarboxylase 1 (GAD1)] are reduced in the dorsolateral prefrontal cortex (dlPFC) in subjects with major depressive disorder (MDD). However, no studies have explored the association between these two molecules and its related biological processes in MDD because of limited postmortem sample availability. Data sharing using the Stanley neuropathology consortium integrative database (SNCID), a web-based tool that integrates datasets from the same postmortem brain samples, allowed us to reanalyze existing postmortem data efficiently. We found two datasets where the mRNA levels of GAD1 and SLC1A2 in subregions of the dlPFC were significantly and marginally lower in subjects with MDD (n = 15) than in controls (n = 15) (p = 0.045 and 0.057, respectively). In addition, there was a positive correlation between these two molecules (n = 30, p < 0.05). Spearman’s rank correlation analysis using all available datasets revealed that the expression levels of both GAD1 and SLC1A2 mRNAs were commonly correlated with the expression levels of several neuropathological markers in the dlPFC in all of the SNCID subjects (n = 60, p < 0.001). Most of these markers are known to be involved in the RAF/MEK/ERK signal transduction pathway. This exploratory study provides an initial step for future studies to investigate an association between the reductions in SLC1A2 and GAD1 mRNA expression and their relation to the attenuation of the RAF/MEK/ERK signaling pathway in the dlPFC in MDD. The integration of the existing archival data may shed light on one important aspect of the pathophysiology of MDD.

Alcaro A, Panksepp J, Witczak J, Hayes DJ, Northoff G (2010) Is subcortical-cortical midline activity in depression mediated by glutamate and GABA? A cross-species translational approach. Neurosci Biobehav Rev 34:592–605. doi:10.1016/j.neubiorev.2009.11.023 PubMedCrossRef

Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, Carvalho RF, Carvalho AP, Duarte CB (2005) Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 12:1329–1343. doi:10.1038/sj.cdd.4401662 PubMedCrossRef

Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501–511. doi:10.1038/mp.2008.106 PubMedCentralPubMedCrossRef

Beart PM, O’Shea RD (2007) Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 150:5–17. doi:10.1038/sj.bjp.0706949 PubMedCentralPubMedCrossRef

Bender R, Lange S (2001) Adjusting for multiple —when and how? J Clin Epidemiol 54:343–349. doi:10.1016/S0895-4356(00)00314-0 PubMedCrossRef

Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653–15658. doi:10.1073/pnas.0507901102 PubMedCentralPubMedCrossRef

Davidson RJ, Putnam KM, Larson CL (2000) Dysfunction in the neural circuitry of emotion regulation—a possible prelude to violence. Science 289:591–594. doi:10.1126/science.289.5479.591 PubMedCrossRef

Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS (2007) A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61:661–670. doi:10.1016/j.biopsych.2006.05.047 PubMedCrossRef

Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN (2001) Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 77:916–928. doi:10.1046/j.1471-4159.2001.00300.x PubMedCrossRef

Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60:804–815. doi:10.1001/archpsyc.60.8.804 PubMedCrossRef

Dwivedi Y, Rizavi HS, Conley RR, Pandey GN (2006) ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry 11:86–98. doi:10.1038/sj.mp.4001744 PubMedCrossRef

Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN (2009) Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 12:1337–1354. doi:10.1017/S1461145709990575 PubMedCrossRef

Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 101:12604–12609. doi:10.1073/pnas.0405077101 PubMedCentralPubMedCrossRef

Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43:1173–1179. doi:10.1016/S0028-3908(02)00217-4 PubMedCrossRef

Higgs BW, Elashoff M, Richman S, Barci B (2006) An online database for brain disease research. BMC Genom 7:70. doi:10.1186/1471-2164-7-70 CrossRef

Hu WH, Walters WM, Xia XM, Karmally SA, Bethea JR (2003) Neuronal glutamate transporter EAAT4 is expressed in astrocytes. Glia 44:13–25. doi:10.1002/glia.10268 PubMedCrossRef

Karolewicz B, Maciag D, O’Dwyer G, Stockmeier CA, Feyissa AM, Rajkowska G (2010) Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 13:411–420. doi:10.1017/S1461145709990587 PubMedCentralPubMedCrossRef

Kim S, Webster MJ (2010) The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 35:473–482. doi:10.1038/npp.2009.151 PubMedCentralPubMedCrossRef

Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB (2011) Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 226:2484–2493. doi:10.1002/jcp.22609 PubMedCentralPubMedCrossRef

Kim S, Zavitsanou K, Gurguis G, Webster MJ (2012) Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the stanley neuropathology integrative database. Eur Neuropsychopharmacol 22:683–694. doi:10.1016/j.euroneuro.2012.01.010 PubMedCrossRef

Koenigs M, Grafman J (2009) The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 201:239–243. doi:10.1016/j.bbr.2009.03.004 PubMedCentralPubMedCrossRef

Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, Lopez JF, Watson SJ (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55:225–233. doi:10.1016/j.biopsych.2003.09.017 PubMedCrossRef

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3 K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279. doi:10.1016/j.advenzreg.2006.01.004 PubMedCrossRef

Milham MP, Banich MT, Webb A, Barad V, Cohen NJ, Wszalek T, Kramer AF (2001) The relative involvement of anterior cingulate and prefrontal cortex in attentional control depends on nature of conflict. Brain Res Cogn Brain Res 12:467–473. doi:10.1016/s0926-6410(01)00076-3 PubMedCrossRef

Mueller HT, Meador-Woodruff JH (2004) NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res 71:361–370. doi:10.1016/j.schres.2004.02.016 PubMedCrossRef

Oh DH, Son H, Hwang S, Kim SH (2012) Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. Eur Neuropsychopharmacol 22:330–338. doi:10.1016/j.euroneuro.2011.09.001 PubMedCrossRef

Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y (2008) Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 11:1047–1061. doi:10.1017/s1461145708009000 PubMedCrossRef

Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53–62. doi:10.1016/S0248-4900(01)01125-X PubMedCrossRef

Popoli M, Yan Z, McEwen BS, Sanacora G (2011) The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13:22–37. doi:10.1038/nrn3138 PubMedCentralPubMed

Qi X, Lin W, Li J, Li H, Wang W, Wang D, Sun M (2008) Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 31:278–285. doi:10.1016/j.nbd.2008.05.003 PubMedCrossRef

Qi H, Mailliet F, Spedding M, Rocher C, Zhang X, Delagrange P, McEwen B, Jay TM, Svenningsson P (2009) Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 56:37–46. doi:10.1016/j.neuropharm.2008.06.068 PubMedCrossRef

Rajkowska G, O’Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ (2007) GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropharmacology 32:471–482. doi:10.1038/sj.npp.1301234

Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K, Fukuda M, Kato N (2004) Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50:1–11. doi:10.1016/j.neures.2004.05.003 PubMedCrossRef

Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705–713. doi:10.1001/archpsyc.61.7.705 PubMedCrossRef

Sanchez-Huertas C, Rico B (2011) CREB-dependent regulation of GAD65 transcription by BDNF/TrkB in cortical interneurons. Cereb Cortex 21:777–788. doi:10.1093/cercor/bhq150 PubMedCrossRef

Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G (2009) Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4:e6585. doi:10.1371/journal.pone.0006585 PubMedCentralPubMedCrossRef

Sibille E, Morris HM, Kota RS, Lewis DA (2011) GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 14:721–734. doi:10.1017/S1461145710001616 PubMedCentralPubMedCrossRef

Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5:173–183. doi:10.1038/nrn1346 PubMedCrossRef

Thompson M, Weickert CS, Wyatt E, Webster MJ (2009) Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 43:970–977. doi:10.1016/j.jpsychires.2009.02.005 PubMedCrossRef

Tordera RM, Garcia-Garcia AL, Elizalde N, Segura V, Aso E, Venzala E, Ramirez MJ, Del Rio J (2011) Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. Eur Neuropsychopharmacol 21:23–32. doi:10.1016/j.euroneuro.2010.06.016 PubMedCrossRef

Torrey EF, Bowcut JC (2013) SMRI contributions to drug development for schizophrenia and bipolar disorder. Schizophr Bull 39:481–482. doi:10.1093/schbul/sbt039 PubMedCentralPubMedCrossRef

Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000) The stanley foundation brain collection and neuropathology consortium. Schizophr Res 44:151–155. doi:10.1016/S0920-9964(99)00192-9 PubMedCrossRef

Tzingounis AV, Wadiche JI (2007) Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci 8:935–947. doi:10.1038/nrn2274 PubMedCrossRef

Xing G, Chavko M, Zhang LX, Yang S, Post RM (2002) Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58:21–30. doi:10.1016/S0920-9964(01)00388-7 PubMedCrossRef

Xing GQ, Russell S, Webster MJ, Post RM (2004) Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 7:143–153. doi:10.1017/s1461145703004000 PubMedCrossRef

Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK (2010) Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 124:164–169. doi:10.1016/j.jad.2009.10.017 PubMedCentralPubMedCrossRef

Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA (2010) Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 58:465–473. doi:10.1016/j.neuropharm.2009.09.005 PubMedCrossRef

Zink M, Rapp S, Donev R, Gebicke-Haerter PJ, Thome J (2011) Fluoxetine treatment induces EAAT2 expression in rat brain. J Neural Transm 118:849–855. doi:10.1007/s00702-010-0536-y PubMedCrossRef

Titel: An association between the reduced levels of SLC1A2 and GAD1 in the dorsolateral prefrontal cortex in major depressive disorder: possible involvement of an attenuated RAF/MEK/ERK signaling pathway
verfasst von: Dong Hoon Oh
Daeyoung Oh
Hyeon Son
Maree J. Webster
Cyndi S. Weickert
Seok Hyeon Kim
Publikationsdatum: 01.07.2014
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 7/2014
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1189-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

The effects of 1 Hz rTMS preconditioned by tDCS on gait kinematics in Parkinson’s disease

Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex

Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus

Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis

VPS35 Parkinson’s disease phenotype resembles the sporadic disease